Introduction
============

Gastric cancer (GC) is one of the most common and deadly malignancies worldwide, with an annual incidence of about 1 million cases.[@b1-ott-9-4661] Although multidisciplinary treatment, including adjuvant chemotherapy and radiotherapy, has advanced, surgical resection remains the main treatment choice. However, overall postoperative survival is still poor, given the relatively late stage at which the diagnosis is usually made.[@b2-ott-9-4661],[@b3-ott-9-4661] Hence, interest is increasing in identifying high-risk patients as soon as possible to improve clinical decision making and contribute to a more rational targeted therapy.

The American Joint Committee on Cancer tumor--node--metastasis (TNM) system, the reference standard for predicting GC prognosis, depends on postoperative histologic findings. Identifying preoperative indicators of postoperative survival in these patients would thus be valuable.

The host's systemic inflammatory response (SIR) is a critical component of tumor progression.[@b4-ott-9-4661] As a state of chronic inflammation, SIR is an essential component in carcinogenesis, promoting both proliferation and migration.[@b5-ott-9-4661]--[@b7-ott-9-4661] Recent studies have shown that SIR is associated with poor outcomes in various types of cancer.[@b8-ott-9-4661]--[@b10-ott-9-4661]

Several SIR-based prognostic indexes have been explored for GC, including the Glasgow prognostic score (GPS), the neutrophil lymphocyte ratio (NLR), and the platelet lymphocyte ratio (PLR).[@b11-ott-9-4661]--[@b13-ott-9-4661] Of these, the GPS is regarded as the most promising predictor of postoperative survival. More than 70 studies worldwide have investigated the relationship between the GPS and postoperative survival in several types of cancer.[@b14-ott-9-4661] Based on elevated serum concentrations of both C-reactive protein (CRP) and hypoalbuminemia, the GPS reflects both systemic inflammation and malnutrition.[@b15-ott-9-4661] Low albumin concentrations are associated with poor survival in GC, and the strength of this association depends on the presence of SIR.[@b16-ott-9-4661] Lien et al also concluded that preoperative serum albumin concentration, in conjunction with TNM stage, accurately predicted long-term outcomes in GC.[@b17-ott-9-4661] In addition, a recent meta-analysis of nine studies concluded that an elevated NLR was associated with poorer rates of survival in GC patients.[@b18-ott-9-4661]

Therefore, we hypothesized that an index based on preoperative serum albumin concentration and NLR would predict postoperative survival better than other prognostic scores. The results of our retrospective analysis indicate that the COA-NLR does predict the overall survival (OS) better than other prognostic scores.

Methods
=======

This study complied with the standards of the Declaration of Helsinki and was approved by the Ethical Committee of Sun Yat-Sen University Cancer Center. Every patient provided written informed consent before being included in this study.

Patient selection
-----------------

We retrospectively analyzed data from all patients with GC who underwent curative resection (D2 lymphadenectomy) at the Cancer Center of Sun Yat-Sen University between September 2000 and November 2012. All patients had stage I to III adenocarcinoma of the stomach, confirmed by pathologic analyses of postoperative histological specimens. Cancers were staged according to the seventh edition of the American Joint Committee on Cancer TNM staging system.[@b19-ott-9-4661]

After surgery, the patient's case was discussed at a multidisciplinary meeting involving surgeons, oncologists, pathologists, and radiologists. Using current guidelines, patients with high-risk stage II or III GC and no marked comorbidities precluding chemotherapy were offered primarily 5-fluorouracil-based adjuvant chemotherapy.[@b20-ott-9-4661]

Patients were excluded if laboratory data were incomplete, if there were clinical evidence of infection or inflammatory conditions, if they had undergone neoadjuvant chemotherapy or radiotherapy, or if they had received preoperative intravenous nutrition or anti-inflammatory therapy.

Data collection
---------------

Within 1 week before surgery, routine laboratory measurements, including serum concentrations of CRP and albumin; and lymphocyte, neutrophil, and platelet counts, were obtained from all patients and logged in the medical record. Performance status (Eastern Cooperative Oncology Group) was recorded at the time of diagnosis. In addition, preoperative body weight loss was recorded, defined as "none", "limited" (≤10%), or "severe" (\>10%).[@b21-ott-9-4661] Papillary and moderately differentiated histological grades were categorized as well-differentiated cancers, and signet ring cell, mucinous types, and undifferentiated grades were categorized as poorly differentiated cancers.[@b22-ott-9-4661]

Patients were followed regularly at 6- to 12-month intervals with laboratory tests, dynamic computed tomography scans, and gastroscopic examinations. The last follow-up date was July 8, 2014. OS was measured from the date of surgery to the date of death or to the last follow-up visit. Thus, data were censored as of July 8, 2014.

The NLR and PLR were defined as the absolute neutrophil count and platelet count, respectively, divided by the absolute lymphocyte count. The GPS was calculated from serum CRP and albumin concentrations. As reported previously,[@b23-ott-9-4661] standard clinical thresholds were used for some common variables, including CRP and albumin concentrations; and lymphocyte, neutrophil, and platelet counts ([Table 1](#t1-ott-9-4661){ref-type="table"}).

Patients who had a CRP concentration \>10 mg/L and an albumin concentration \<35 g/L were assigned a score of 2. Patients with only one or neither of these concentrations were assigned a score of 1 or 0, respectively.[@b15-ott-9-4661] The COA-NLR was calculated as follows: patients with both hypoalbuminemia (\<35 g/L) and an elevated NLR (≥2.3) were allocated a score of 2, and patients with one or neither were allocated a score of 1 or 0, respectively. The optimal thresholds for other variables were defined using the Youden index and receiver operating characteristic (ROC) curve analyses.

Statistical methods
-------------------

Patient characteristics are summarized as mean and 95% confidence interval (CI). Differences among the three groups (ie, patients with prognostic scores of 0, 1, or 2) were analyzed with Pearson's chi-squared test. OS was calculated with the Kaplan--Meier method, and differences were assessed by log-rank tests. The Shapiro--Wilk test was used to assess the normality of distribution. If a continuous variable was proven for the assumption of linearity in the logit, it was categorized by the optimal cutoff value. ROC curves were plotted, and the optimum cutoff value for predicting OS was determined with Youden index (maximum \[sensitivity + specificity\] minus 1). Unadjusted and multivariate analyses were performed to identify potential prognostic factors. Variables significantly associated with OS at the 0.05 level in the unadjusted analysis were considered for inclusion in a multivariate Cox proportional hazards model.[@b9-ott-9-4661],[@b24-ott-9-4661],[@b25-ott-9-4661] The discriminatory ability of each prognostic score was expressed as the area under the curve (AUC). All data were analyzed with the SPSS statistical software package, version 19.0 (IBM Corporation, Armonk, NY, USA). Alpha was set at 0.05, and all tests were two-tailed.

Results
=======

Of the 1,017 patients evaluated, 96 had incomplete laboratory data, 24 had clinical evidence of infection or inflammatory conditions, 13 had undergone neoadjuvant chemotherapy or radiotherapy, and eleven had received preoperative intravenous nutrition or anti-inflammatory therapy. In the 873 eligible patients (594 males and 279 females), the median (range) age was 59 (19--89) years. Median (range) follow-up period was 36 (1--165) months. The 471 patients who died before July 8, 2014 (54.0%) were included in the analysis; 402 (46.0%) patients were alive at the last follow-up. Of the 873 patients, only six patients died of other diseases or reasons and most of the patients died of tumor recurrence and metastasis. During the observation period, 13 of 108 stage I patients died and ten (9%) patients died of recurrence of cancer at last follow-up.

The COA-NLR score was 0 for 488 patients, 1 for 328 patients, and 2 for 57 patients. Albumin concentrations and the NLR were inversely correlated (*r*=−0.14; *P*\<0.001). Groups with the three scores differed significantly according to mean age, tumor size, tumor location, performance status, preoperative body weight loss, metastatic lymph node ratio, histological grade, and TNM stage ([Table 2](#t2-ott-9-4661){ref-type="table"}) and by OS. OS was 44.9% in patients with a COA-NLR score of 0, 29.8% in patients with a score of 1, and 20.3% in patients with a score of 2 (*P*\<0.001). Mean survival was also significantly longer in patients with a COA-NLR of 0 (87.7 months) than in those with a score of 1 (65.3 months) or 2 (51.8 months; [Table 3](#t3-ott-9-4661){ref-type="table"}; [Figure 1](#f1-ott-9-4661){ref-type="fig"}).

Unadjusted analysis indicated that age, tumor size, tumor location, preoperative body weight loss, histological grade, metastatic lymph node ratio, TNM stage, neutrophils, CRP, albumin, NLR, PLR, GPS, and COA-NLR score were associated with OS. Multivariate analysis indicated that COA-NLR score was independently associated with OS (hazard ratio \[HR\], 1.35; 95% CI, 1.12 to 1.63; *P*=0.002), as were TNM stage, metastatic lymph node ratio, preoperative body weight loss, histological grade, tumor location, and age ([Table 4](#t4-ott-9-4661){ref-type="table"}).

Because the COA-NLR was closely associated with the above variables, its prognostic value was further investigated with subgroup analysis. Prognostic significance was still maintained when patients were stratified by age (\<60 years, *P*=0.002; ≥60 years, *P*\<0.001), tumor location (upper stomach, *P*=0.009; middle stomach, *P*=0.30, lower stomach, *P*\<0.001), preoperative body weight loss (none, *P*\<0.001; limited, *P*=0.090; severe, *P*=0.002), histological grade (well differentiated, *P*\<0.001; poorly differentiated, *P*\<0.001), metastatic lymph node ratio (\<0.1, *P*\<0.001; ≥0.1, *P*=0.02), and TNM stage (stage I, *P*=0.001; stage II, *P*=0.006; stage III, *P*=0.02).

To further assess the discriminatory ability of the indexes, we compared the areas under the ROC curve. The COA-NLR index had a significantly higher AUC value than the others, including the GPS, which has been regarded as a prognostic milestone ([Table 5](#t5-ott-9-4661){ref-type="table"}; [Figure 2](#f2-ott-9-4661){ref-type="fig"}). Of note, in stage I--II GC, the COA-NLR was superior to other established inflammation-based prognostic indexes in terms of its prognostic ability, with a higher AUC value (0.66; *P*\<0.001), and it divided patients into subgroups more accurately (all *P*-values for association with OS were \<0.05; [Figure 3](#f3-ott-9-4661){ref-type="fig"}). In addition, the AUC value of the COA-NLR was the highest for patients with stage I GC (AUC value: 0.72; *P*=0.009).

Discussion
==========

We determined the prognostic value of the COA-NLR for patients with GC. The COA-NLR score had a greater AUC than the other indexes studied and it was associated with more aggressive tumor features. We believe it can be used as an independent marker of poor prognosis in patients undergoing curative resection for GC without neoadjuvant treatment.

The link between inflammation and cancer is well established, although the underlying mechanism is not completely understood. Inflammatory responses can induce chronic oxidative stress and produce oxygen-free radicals, which can stimulate carcinogenesis, proliferation, and progression.[@b26-ott-9-4661] Furthermore, proinflammatory cytokines release tumor-associated leukocytes that can generate various inflammatory cytokines, including tumor necrosis factor-alpha, interleukin, and vascular endothelial growth factor, which facilitate cancer growth, invasion, and metastasis[@b7-ott-9-4661],[@b27-ott-9-4661],[@b28-ott-9-4661] and suppress antitumor immunity, which further promotes proliferation and progression.[@b29-ott-9-4661]

Inflammation-based prognostic indexes, such as the NLR, PLR, and GPS, have been reported to have value in patients with various types of cancer, including GC.[@b30-ott-9-4661]--[@b32-ott-9-4661] In the meta-analysis described earlier of ten studies with a pooled sample size of 2,952 patients, OS was significantly better in patients with low NLR values, and the pooled HR was significant (HR, 1.83; 95% CI, 1.62 to 2.07).[@b33-ott-9-4661]

Hypoalbuminemia, as a state of malnutrition, also independently predicts survival in patients with GC.[@b16-ott-9-4661] Albumin, which preferentially accumulates in tumor tissue, is a major energy and nutrition source for tumor growth. Additionally, hypoalbuminemia can impair cellular immunity, which eventually results in a poor prognosis. Al-Shaiba et al confirmed an association between hypoalbuminemia, inflammation, and poor outcome in patients with colorectal liver metastases.[@b34-ott-9-4661] Thus, albumin concentration is not only a nutritional marker, it is also an inflammatory response marker. Accumulating evidence indicates that hypoalbuminemia is associated with poor survival in several primary malignancies, including GC.[@b35-ott-9-4661]--[@b37-ott-9-4661]

Therefore, we speculated that an index based on preoperative serum albumin concentration and the NLR might be a promising tool in predicting outcomes in GC. In the current study, we found that the COA-NLR was a valuable predictor of OS independent of TNM stage. Furthermore, it was significantly associated with some variables indicating poor prognosis, including higher TNM stage, more metastatic lymph nodes, and larger tumor size. Obviously, an elevated COA-NLR score was associated with more aggressive tumor features. In subgroup analyses, the prognostic accuracy of the COA-NLR was still substantial, although it was not significant in patients with tumors located in the middle stomach and limited preoperative body weight loss. However, only eight patients with tumors located in the middle stomach and only 18 with preoperative weight loss had a COA-NLR score of 2, so these results should be viewed with caution.

The PLR did not independently predict OS in the multivariate model that included the COA-NLR. Therefore, these data suggested that the COA-NLR might have more prognostic value than the PLR in these patients. In fact, Kim et al drove a similar conclusion that the NLR, rather than the PLR, was an independent prognostic factor for GC.[@b11-ott-9-4661] Future studies are needed to further assess the potential prognostic value of the PLR in GC.

In our study, adjuvant chemotherapy was not associated with OS in the unadjusted analysis, although mean survival time was longer in patients with adjuvant chemotherapy than in those without adjuvant chemotherapy (74.5 vs 80.2 months), a finding consistent with Han et al.[@b38-ott-9-4661] They retrospectively analyzed 7,954 patients undergoing D2 gastrectomy for GC in Korea. Multivariate analysis identified age, sex, location, depth of invasion, number of metastatic lymph nodes, and number of examined lymph nodes as covariates associated with survival. However, adjuvant chemotherapy failed to demonstrate significance in the multivariate Cox model. In recent years, several large clinical trials have found substantial benefits of adjuvant chemotherapy for patients with GC after curative resection, especially in stage-matched analysis.[@b39-ott-9-4661],[@b40-ott-9-4661] We speculated some confounding factors, namely TNM stage or adjuvant chemotherapy administration, might influence the prognostic value of adjuvant chemotherapy.

To further evaluate the discriminatory ability of the inflammation-based prognostic scores, we compared the AUCs. The COA-NLR had a higher AUC value than those of the other prognostic scores, suggesting that the COA-NLR might be a better marker of systemic inflammation and malnutrition than the GPS, PLR, and NLR scores. Therefore, COA-NLR was not only capable of classifying patients with GC into three independent groups before surgery; it was also a potential predictor of OS in such patients.

Our index has predictive capabilities, especially in patients with stage I--II GC, so it may be more suitable for predicting the outcome in such patients than other prognostic indexes. Although the survival curve for the NLR is identical to that of patients with a COA-NLR score of 0, the COA-NLR more accurately assessed prognosis because it has a higher AUC value. OS in patients with a COA-NLR score of 2 was significantly lower than in patients with an NLR score of 1 (35.5% vs 46.3%; *P*\<0.001). Obviously, the COA-NLR score could more accurately identify high-risk patients with stage I--II GC. In addition, the COA-NLR score classified patients into three independent groups, which effectively stratifies prognosis in patients undergoing curative resection for GC. More importantly, we found that patients with stage I GC alone had the most to gain from an improved ability to predict poor outcome. It is worthy of being further validated in future studies.

The preoperative COA-NLR score may identify patients with a poor prognosis. If so, resources can be better allocated to patients most at risk, such as closer follow-up and more aggressive adjuvant chemotherapy. In addition, such patients may benefit from targeted anti-inflammatory therapy after surgery.[@b41-ott-9-4661] Furthermore, the COA-NLR score may be able to guide the use of some anti-inflammatory agents. Finally, whether a targeted preoperative nutritional intervention or neoadjuvant therapy could improve outcomes in patients with COA-NLR score of 2 is also worth exploring.

Strengths and limitations of the study
--------------------------------------

Limitations of our research include the fact that it was done at a single center and we did not have data on disease-free survival. We also had no information on nutritional support and neoadjuvant therapy. Although the study was retrospective and the number of patients with some scores was small, overall it involved a large and representative sample of patients who underwent uniform surgical procedures, laboratory tests, and follow-up throughout the entire study period. Thus, we believe that the evidence supports the claim that the COA-NLR has prognostic value.

Conclusion
==========

We believe our study supports the usefulness of the preoperative COA-NLR score for predicting the OS in patients with GC undergoing curative resection without neoadjuvant treatment.

We thank all the people who helped us in this study.
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![Comparison of the areas under the ROC for predicting overall survival of 873 patients undergoing curative resection without neoadjuvant treatment for gastric cancer (*P*\<0.001).\
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###### 

Inflammation-based scoring indexes for predicting postoperative survival in patients with gastric cancer

  Scoring system                                                                Score
  ----------------------------------------------------------------------------- -------
  **Neutrophil lymphocyte ratio**                                               
  Neutrophil count:lymphocyte count \<2.3                                       0
  Neutrophil count:lymphocyte count ≥2.3                                        1
  **Platelet lymphocyte ratio**                                                 
  Platelet count:lymphocyte count \<117                                         0
  Platelet count:lymphocyte count ≥117                                          1
  **Glasgow prognostic score**                                                  
  CRP (≤10 mg/L) and albumin (≥35 g/L)                                          0
  CRP (≤10 mg/L) and albumin (\<35 g/L)                                         1
  CRP (\>10 mg/L) and albumin (≥35 g/L)                                         1
  CRP (\>10 mg/L) and albumin (\<35 g/L)                                        2
  **Combination of albumin concentration** + **neutrophil: lymphocyte ratio**   
  Albumin (≥35 g/L) and neutrophil count:lymphocyte count \<2.3                 0
  Albumin (≥35 g/L) and neutrophil count:lymphocyte count ≥2.3                  1
  Albumin (\<35 g/L) and neutrophil count:lymphocyte count \<2.3                1
  Albumin (\<35 g/L) and neutrophil count:lymphocyte count ≥2.3                 2

**Abbreviation:** CRP, C-reactive protein.

###### 

Relationships between COA-NLR and clinico-pathologic characteristics of 873 patients undergoing curative resection without neoadjuvant treatment for gastric cancer

  Characteristic                    COA-NLR score   *P*-value        
  --------------------------------- --------------- ----------- ---- --
  **Sex**                           0.06                             
  Male                              317             239         38   
  Female                            171             89          19   
  **Age (years)**                   0.001                            
  \<60                              291             156         25   
  ≥60                               197             172         32   
  **Tumor size (cm)**               \<0.001                          
  ≤3                                182             73          10   
  \>3                               306             255         47   
  **Tumor location**                0.02                             
  Upper                             182             159         29   
  Middle                            100             54          8    
  Lower                             206             115         20   
  **Performance status**            0.04                             
  0                                 152             92          12   
  1                                 324             232         41   
  2                                 12              4           4    
  **Preoperative weight loss**      0.02                             
  None                              250             157         26   
  Limited                           195             136         18   
  Severe                            43              35          13   
  **Adjuvant chemotherapy**         0.08                             
  No                                178             98          15   
  Yes                               310             230         42   
  **Histological grade**            0.004                            
  Well differentiated               91              87          19   
  Poorly differentiated             397             241         38   
  **Metastatic lymph node ratio**   \<0.001                          
  \<0.1                             222             99          20   
  ≥0.1                              266             229         37   
  **TNM stage (I/II/III)**          \<0.001                          
  I                                 82              23          3    
  II                                114             59          12   
  III                               292             246         42   

**Abbreviations:** COA-NLR, the combination of albumin level and neutrophil lymphocyte ratio; TNM, tumor--node--metastasis staging.

###### 

Factors affecting overall survival among 873 patients undergoing curative resection without neoadjuvant treatment for gastric cancer

  Characteristic                                                     Patients, n (%)   Overall survival, months (95% CI)   *P*-value[a](#tfn3-ott-9-4661){ref-type="table-fn"}
  ------------------------------------------------------------------ ----------------- ----------------------------------- -----------------------------------------------------
  **Sex**                                                            0.46                                                  
  Male                                                               594 (68.0)        79.7 (73.3 to 86.0)                 
  Female                                                             279 (32.0)        83.3 (74.5 to 92.1)                 
  **Age (years)**                                                    \<0.001                                               
  \<60                                                               472 (54.1)        87.9 (81.1 to 94.8)                 
  ≥60                                                                401 (45.9)        67.8 (60.5 to 75.1)                 
  **Tumor size (cm)**                                                \<0.001                                               
  ≤3                                                                 265 (30.4)        94.5 (85.6 to 103.4)                
  \>3                                                                608 (69.6)        71.1 (65.1 to 77.1)                 
  **Tumor location**                                                 \<0.001                                               
  Upper                                                              370 (42.4)        54.3 (48.0 to 60.6)                 
  Middle                                                             162 (18.6)        81.9 (70.0 to 93.9)                 
  lower                                                              341 (39.1)        97.5 (89.5 to 105.5)                
  **Performance status**[b](#tfn4-ott-9-4661){ref-type="table-fn"}   0.98                                                  
  0                                                                  256 (29.3)        74.7 (64.9 to 84.4)                 
  1                                                                  597 (68.4)        79.5 (73.3 to 85.6)                 
  2                                                                  20 (2.3)          71.3 (42.3 to 100.3)                
  **Preoperative weight loss**                                       0.001                                                 
  None                                                               433 (49.6)        87.9 (80.4 to 95.3)                 
  Limited (≤10%)                                                     349 (40.0)        71.0 (53.5 to 78.4)                 
  Severe (\>10%)                                                     91 (10.4)         60.0 (45.2 to 74.7)                 
  **Adjuvant chemotherapy**                                          0.11                                                  
  No                                                                 291 (33.3)        74.5 (65.3 to 83.7)                 
  Yes                                                                582 (66.7)        80.2 (74.2 to 86.2)                 
  **Histological grade**[c](#tfn5-ott-9-4661){ref-type="table-fn"}   0.03                                                  
  Well differentiated                                                197 (22.6)        82.4 (72.9 to 92.0)                 
  Poorly differentiated                                              676 (77.4)        76.9 (71.0 to 82.8)                 
  **Metastatic lymph node ratio**                                    \<0.001                                               
  \<0.1                                                              341 (39.1)        116.2 (109.0 to 123.5)              
  ≥0.1                                                               532 (60.9)        52.4 (46.8 to 58.1)                 
  **TNM stage (I/II/III)**                                                                                                 \<0.001
  I                                                                  108 (12.4)        122.7 (115.2 to 130.1)              
  II                                                                 185 (21.2)        111.0 (100.5 to 121.6)              
  III                                                                580 (66.4)        55.8 (50.2 to 61.4)                 
  **Neutrophil count, 10^9^/L**                                      \<0.001                                               
  \<7.5                                                              812 (93.0)        82.2 (76.8 to 87.6)                 
  ≥7.5                                                               61 (7.0)          37.1 (26.1 to 48.1)                 
  **Lymphocyte count, 10^9^/L**                                      0.70                                                  
  \<3                                                                812 (93.0)        79.5 (74.1 to 84.8)                 
  ≥3                                                                 61 (7.0)          70.8 (54.7 to 86.9)                 
  **Platelet count, 10^9^/L**                                        0.72                                                  
  \<400                                                              803 (92.0)        79.5 (74.1 to 84.9)                 
  ≥400                                                               70 (8.0)          73.4 (57.7 to 89.0)                 
  **C-reactive protein, mg/L**                                       \<0.001                                               
  ≤10                                                                494 (56.6)        47.6 (44.5 to 50.7)                 
  \>10                                                               107 (12.3)        28.7 (24.1 to 33.4)                 
  **Albumin, g/L**                                                   \<0.001                                               
  \<35                                                               98 (11.2)         58.5 (44.5 to 72.4)                 
  ≥35                                                                775 (88.8)        80.4 (75.1 to 85.7)                 
  **Neutrophil lymphocyte ratio**                                    \<0.001                                               
  \<2.3                                                              529 (60.6)        86.1 (79.8 to 92.4)                 
  ≥2.3                                                               344 (39.4)        64.0 (56.3 to 71.7)                 
  **Platelet lymphocyte ratio**                                      0.009                                                 
  \<117                                                              365 (41.8)        84.9 (77.2 to 92.7)                 
  ≥117                                                               508 (58.2)        74.4 (67.7 to 81.2)                 
  **Glasgow prognostic score**                                       \<0.001                                               
  0                                                                  464 (53.2)        48.3 (45.1 to 51.5)                 
  1                                                                  98 (11.2)         33.2 (27.6 to 38.8)                 
  2                                                                  39 (4.5)          23.8 (16.8 to 30.8)                 
  **COA-NLR**                                                        \<0.001                                               
  0                                                                  488 (55.9)        87.7 (81.1 to 94.2)                 
  1                                                                  328 (37.6)        65.3 (57.6 to 73.1)                 
  2                                                                  57 (6.5)          51.8 (34.9 to 68.7)                 

**Notes:**

Kaplan--Meier survival analysis.

Eastern Cooperative Oncology group.

Papillary and moderately differentiated histological grades were categorized as well-differentiated cancers, and signet ring cell, mucinous types, and undifferentiated grades were categorized as poorly differentiated cancers.

**Abbreviations:** CI, confidence interval; COA-NLR, the combination of albumin level and neutrophil lymphocyte ratio; TNM, tumor--node--metastasis staging.

###### 

Univariate and multivariate analyses of risk factors for overall survival in 873 patients undergoing curative resection without neoadjuvant treatment for gastric cancer

  Characteristic                                      Unadjusted analysis    Multivariate analysis                         
  --------------------------------------------------- ---------------------- ----------------------- --------------------- ---------
  Sex (male/female)                                   0.93 (0.764 to 1.13)   0.46                    --                    
  Age (\<60/≥60 years)                                1.54 (1.281 to 1.84)   \<0.001                 1.60 (1.28 to 1.98)   \<0.001
  Tumor size (≤3/\>3 cm)                              1.75 (1.41 to 2.17)    \<0.001                 0.92 (0.71 to 1.21)   0.56
  Tumor location (upper/middle/lower)                 0.67 (0.61 to 0.75)    \<0.001                 0.79 (0.69 to 0.89)   \<0.001
  Performance status (0/1/2)                          1.02 (0.85 to 1.23)    0.84                    --                    
  Preoperative body weight loss (no/limited/severe)   1.29 (1.13 to 1.47)    \<0.001                 1.20 (1.03 to 1.41)   0.02
  Adjuvant chemotherapy (no/yes)                      0.86 (0.71 to 1.04)    0.11                    --                    
  Histological grade (well/poorly differentiated)     1.28 (1.03 to 1.61)    0.03                    1.49 (1.10 to 2.02)   0.009
  Metastatic lymph node ratio (\<0.1/≥0.1)            4.26 (3.38 to 5.36)    \<0.001                 2.04 (1.44 to 2.89)   \<0.001
  TNM stage (I/II/III)                                3.29 (2.68 to 4.04)    \<0.001                 1.92 (1.42 to 2.60)   \<0.001
  Neutrophils (\<7.5/≥7.5×10^9^/L)                    2.00 (1.46 to 2.73)    \<0.001                 --                    
  Llymphocytes (\<3/≥3×10^9^/L)                       0.93 (0.64 to 1.35)    0.70                    --                    
  Platelet (\<400/≥400×10^9^/L)                       0.94 (0.67 to 1.33)    0.72                    --                    
  CRP (≤10/\>10 mg/L)                                 1.89 (1.47 to 2.43)    \<0.001                 1.18 (0.90 to 1.56)   0.24
  Albumin (\<35/≥35 g/L)                              1.59 (1.22 to 2.063)   0.001                   --                    
  NLR (\<2.3/≥2.3)                                    1.66 (1.39 to 1.99)    0.001                   --                    
  PLR (\<117/≥117)                                    1.28 (1.06 to 1.54)    0.009                   1.04 (0.82 to 1.32)   0.75
  GPS (0/1/2)                                         1.60 (1.37 to 1.89)    \<0.001                 --                    
  COA-NLR (0/1/2)                                     1.54 (1.34 to 1.77)    \<0.001                 1.35 (1.12 to 1.63)   0.002

**Abbreviations:** CI, confidence interval; COA-NLR, the combination of albumin level and neutrophil lymphocyte ratio; CRP, C-reactive protein; GPS, Glasgow prognostic score; HR, hazard ratio; NLR, neutrophil lymphocyte ratio; PLR, platelet lymphocyte ratio; TNM, tumor--node--metastasis staging.

###### 

Areas under the receiver operating characteristic curves for four inflammation-based prognostic indexes for predicting postoperative survival in 873 patients undergoing curative resection without neoadjuvant treatment for gastric cancer

  Index                         Area under the ROC curve (95% CI)   *P*-value
  ----------------------------- ----------------------------------- -----------
  COA-NLR                       0.62 (0.57 to 0.66)                 \<0.001
  Neutrophil lymphocyte ratio   0.60 (0.55 to 0.64)                 \<0.001
  Glasgow prognostic score      0.58 (0.54 to 0.63)                 \<0.001
  Platelet lymphocyte ratio     0.54 (0.50 to 0.59)                 0.08

**Abbreviations:** CI, confidence interval; COA-NLR, the combination of albumin level and neutrophil lymphocyte ratio; ROC, receiver operating characteristic.

[^1]: These authors contributed equally to this work
